A Randomized, Open-Label, Single-Center, Single-Dose, Two-Way Crossover Study in Healthy Subjects to Determine the Fed Bioequivalence of Oxycodone Tamper Resistant (OTR) 40-mg Tablets to OxyContin 40-mg Tablets.
Phase of Trial: Phase I
Latest Information Update: 11 May 2010
At a glance
- Drugs Oxycodone (Primary)
- Indications Cancer pain; Pain; Postoperative pain
- Focus Pharmacokinetics
- Sponsors Purdue Pharma
- 11 May 2010 Primary endpoints amended as reported by ClinicalTrials.gov.
- 09 Apr 2010 New trial record